The Atlantic Cancer Research Institute congratulates Dr. Adrian Culf, a research scientist at ACRI, who has received a $25,000 New Brunswick Health Research Foundation (NBHRF) grant to make and laboratory test histone deacetylase (HDAC) inhibitors – novel molecules as a potentially useful anti-cancer treatment. HDAC's are more numerous in cancers, making them promising target proteins for cancer therapy.
This grant is the latest in a series of three over the past year to fund this area of Dr. Culf's research. Said Dr. Culf, "This is very much a team effort with the work of other research scientists, research assistants, technicians and students at ACRI as well as collaborations at other NB-based centres: the National Research Council of Canada (NRC), Université de Moncton and Mount Allison University as co-applicants on these successful grants."
"Dr. Culf's research is advancing our ability to therapeutically target specific molecules, like the HDACs, that drive cancer development and progression, "says Dr. Stephen Lewis, Assistant Scientific Director at ACRI. "The financial support provided by NBHRF will allow Dr. Culf to continue to develop his HDAC inhibitors, and I expect that he will make some interesting and exciting discoveries in this field in the near future."
Media coverage :
